On April 1, 2021, Eloxx Pharmaceuticals, Inc., acquired Zikani Therapeutics, Inc., pursuant to that certain Agreement and Plan of Merger, dated April 1, 2021, by and among Eloxx, Delta Merger Sub Acquisition Corporation, a Delaware corporation and direct, wholly owned subsidiary of the Company (“Merger Sub”), and Zikani. Effective as of the effective time of the Merger on April 1, 2021, each of Martijn Kleijwegt, Silvia Noiman and Gregory C. Williams resigned from the Eloxx Board. The resignations were not the result of any disagreements with Eloxx relating to the Eloxx’s operations, policies or practices. Immediately following the effective time of the Merger on April 1, 2021, pursuant to the terms of the Merger Agreement, each of Sumit Aggarwal, Alan Walts and Rajesh Parekh were appointed to the Eloxx Board. Mr. Aggarwal, Dr. Walts and Dr. Parekh will each serve until the Company’s 2021 annual meeting of stockholders, when they are expected to stand for re-election to the Eloxx Board by a vote of the Company’s stockholders. Dr. Walts was also appointed as a member of the Audit Committee of the Eloxx Board. Mr. Aggarwal served as President and Chief Executive Officer of Zikani since 2019. Mr. Aggarwal joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer. Prior to joining Zikani, from 2015 to 2018, Mr. Aggarwal served as acting President and Chief Financial Officer of Progenity, Inc. Dr. Parekh is a General Partner at Advent Life Sciences LLP, which he joined in 2006. During an academic career at Oxford University, he co-founded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC (now UCB SA) in 2003. Dr. Walts serves as Executive Chairman and Director of PIC Therapeutics (since 2016) and Artax Biopharma (since 2017). Dr. Walts is also a founder, Director and Treasurer of The Termeer Foundation, a public 501(c)(3) organization founded in 2019. Effective as of the effective time of the Merger on April 1, 2021, and pursuant to the Merger Agreement, (i) Sumit Aggarwal was appointed as the President and Chief Executive Officer of the Company, and in connection therewith, the Company and Mr. Aggarwal entered into an Employment Agreement effective as of April 1, 2021; and (ii) Vijay Modur, Ph.D. was appointed the Company’s Head of Research and Development, and in connection therewith, the Company and Dr. Modur entered into an Employment Agreement effective as of April 1, 2021. Effective as of the effective time of the Merger on April 1, 2021, the Company appointed Daniel Geffken to serve as the Company’s Interim Chief Financial Officer. On April 1, 2021, the Company and Dr. Williams entered into a Separation Agreement and General Release (the “Separation Agreement”) pursuant to which, among other things, the Company and Dr. Williams agreed that Dr. Williams would separate from service with the Company, resigning from his position as the Chief Executive Officer of the Company and all other offices of the Company, effective as of April 1, 2021.